Media Contacts

For more information contact our media team:

Stacy Sevcik
+1 314 529 3062
Send Email >

Next Event

  • Pharma Market Research Conference

    Parsippany, USA
    Feb1 – 2, 2017

    Learn More

Kantar Health thought leaders are available to comment on a variety of healthcare- and pharma-industry-related topics. In addition, our proprietary data is available for media use, including patient population sizes, treatment rates and patient-reported behaviors and attitudes.

Welcome to the Kantar Health News Room RSS Feed News

Delivering the most current and unique insights on healthcare trends and news about Kantar Health.

Kantar Health Launches New Oncology Platform, Allowing Healthcare Companies to Better Understand Drug Opportunities

Oct 13, 2016

NEW YORK, October 13, 2016—Kantar Health, a leading global healthcare consulting and market research firm, today announced the launch of CancerLandscape™, offering fast navigation of large datasets to better understand oncology drug opportunities and the competitive landscape. This new solution can assist users in evaluating business development and licensing opportunities, identifying novel targets for drug development, comparing company pipelines, and understanding the competitive landscapes in multiple tumor types.

"For the first time, we've aggregated multiple data sources to achieve unprecedented insight that will help identify the tumors that may be of greatest interest for investment or resource deployment," said Cory Lewis, Ph.D., Manager, Oncology Commercial Development, Kantar Health. "In the past, complex data searches such as these were very time-intensive due to manual execution. However, the CancerLandscape platform is easy to navigate, visually impactful and interactive, and it's the one place where clients can quickly view the entire cancer landscape within one data source."

CancerLandscape, an innovative, web-based solution that lets users review more than 2,000 cancer drugs covering more than 175 tumor types, tracks every oncology medicine in development by company, mechanism of action, tumor type, geography and stage of clinical development.

“CancerLandscape combines the breadth of Big Data with the depth of our large team of Ph.D.-level oncology experts who have the clinical and commercial expertise to provide actionable insights,” Lewis said. “Our oncology expertise that people have come to trust has been put into the development of CancerLandscape to provide our clients with the information they need to make the best decisions in one place where they can view the entire cancer landscape.”

About Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP. For more information, please visit www.kantarhealth.com.

Share